Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196): evaluation report

Evaluation Report: contents

01.   Pre-Meeting Briefing prepared by NICE

02.   Submission from the technology manufacturer – Novartis

03.   NICE request to the manufacturer for clarification on their submission

04.   Manufacturer clarification request

05.   Consultee submission – GIST Support UK

06.   Consultee submission – Sarcoma UK

07.   Patient expert personal perspective – Dore

08.   Patient expert personal perspective – Puntis

09.   Clinical expert personal perspective – Wong

10.   Clinical expert personal perspective – Judson

11.   Evidence Review Group report prepared by SHTAC

12.   Erratum To the Evidence Review Group report

13.   Manufacturer factual accuracy check of Evidence Review Group report

14.   Evidence Review Group response to manufacturer factual accuracy check

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report. It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required. If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 27 June 2014